Baxter International Inc. · NYSE:BAX
Baxter International — 2018 Baxter Investor Conference
14 slides from Baxter International's conference presentation, May 21, 2018
Slide 1: Acute Therapies
ACUTE THERAPIES Reaz Rasul GM, Acute Therapies May 21, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter’s financial results, R&D pipeline, including planned product launches (many of which are subject to regulatory approval) and results of clinical trials, business development activities, capital structure, c
Slide 3: Acute Therapies Market Overview
Acute Therapies Market Overview1 Global Market Size Continuous Renal CAGR2 ~$1.9B Replacement Therapy (CRRT) #1 Monitors, CRRT Filters, CRRT Fluids Baxter Position 4% - 5% ~$1.3B Organ Support Therapies (OST) 10% - 12% Therapeutic Plasma Exchange (TPE) & Sepsis Filters, Liver & Lung Offering #1 Baxt
Slide 4: Market Dynamics
Market Dynamics ~6% ~200K AKI Patient Growth Untreated Patients Stable market growth driven Large population of by aging population and undiagnosed CRRT patients2 environmental factors1 Patient Co-Morbidities ~50% Mortality Rate Increasing number of patients Half of patients entering the entering th
Slide 5: Acute Therapies Portfolio
Acute Therapies Portfolio Continuous Renal Replacement Therapy oXiris S 92% First 3-in-1 Sepsis Management Filter $456M TPE 1000/2000 2017 Sales Therapeutic Plasma Prismaflex 8% Exchange 17k+ CRRT Monitors Installed Organ Support CRRT Fluids Therapies Customized for Patient Needs Leading Product Por
Slide 6: Strategic Growth Drivers
Strategic Growth Drivers Portfolio Innovation Market Development Enter Adjacencies ~$150M 400bps 2X 2023 New Product Revenue1 CRRT Penetration Increase Organ Support Therapies (OST) Revenue Over LRP Evidence HCP Generation Education R&D Investment Commercial Optimization Geographic PrisMax Expansion
Slide 7: Acute Therapies Pipeline
Portfolio Market Enter Acute Therapies Pipeline Innovation Development Adjacencies Multiple Geographic Expansion Launches Japan CRRT Geographic PrisMax Digital Health Next Gen Portfolio Expansions Extension Solution Monitor Digital Emerging Market Extracorporeal PrisMax U.S. Citrate Connectivity Sol
Slide 8: Key Launches
Portfolio Market Enter Key Launches Innovation Development Adjacencies $70M+ Continuous innovation PrisMax1 2023 Revenue to grow $1B+ CRRT market opportunity Opportunity Digital Health 100bps Clinical insights from analytics drive Increase in Share increased utilization Geographic $30M+ Focused port
Slide 9: Market Development
Portfolio Market Enter Market Development Innovation Development Adjacencies Initiative Investment Result 6 claims established on PrisMax Evidence Generation $20M Ongoing studies to generate additional Invested across claims multiple programs Peer-to-Peer globally Live training with >3,000 HCPs acro
Slide 10: Grow Organ Support Therapies
Portfolio Market Enter Grow Organ Support Therapies Innovation Development Adjacencies High Growth R&D Optimization Focusing On High-growth & Investing In R&D And Utilizing ICU Presence To High-margin Therapies Evidence Generation Deliver New Therapies Lung Blood Liver Support Purification Support U
Slide 11: Transformation Opportunities
Transformation Opportunities Continuum Of Care Expansion Breakthrough Technologies Enable AKI Management from early Advancement of core technologies to diagnosis to recovery address unmet customer needs Early Diagnosis Treatment Post Treatment Today Future Future Opportunity Opportunity Continuum Of
Slide 12: Acute Therapies Summary
Acute Therapies Summary Leadership position in growing market with multiple expansion opportunities Well-positioned to deliver sustainable growth of 8% - 9% through innovation and market development1 Significant investment in Organ Support Therapies to drive competitive differentiation Focused on tr
Slide 13: References
References Market Dynamics (Slide 4) 1) Acute Kidney Injury. Based on publicly available data from Premier and Sovereign government databases, as well as internal estimates 2) Based on internal estimates 3) Med Sci Monit. 2016; 22: 3849–3859. Published online 2016 Oct 20. doi: 10.12659/MSM.897760 4)
Slide 14: 2018 Investor Conference
— 2018 Investor Conference a
Baxter International — 2018 Baxter Investor Conference on 6ix